A Phase 3 interventional study of Faricimab and Sham Procedure in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 320 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing faricimab in Macular Edema — 1 open to participants now, 3 under way, none of them phase 3. faricimab · Macular Edema.
Among the 13 studies testing faricimab in Macular Edema, this one has the largest enrollment, is one of 2 that started in 2020, is one of 7 in phase 3, and was the 5th registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →1 of the 13 studies testing faricimab in Macular Edema is open now. Recruiting first, the newest first:
Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust
Ages 18+
faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2020.
This study's enrollment of 1,479 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 229 across the 13 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 13 have an industry lead sponsor. The 6 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
28 studies in Macular Edema by Hoffmann-La Roche: 1 open now, 5 under way, 1 of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one has the largest enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2020, is one of 14 in phase 3, and was the 13th registered.
Hoffmann-La Roche’s Macular Edema studies by the year they started, since 2007.
2 of the studies testing faricimab in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05610319McMaster UniversityTreat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial | 2026-12 |
| NCT05224102Genentech, Inc.A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | 2027-01-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing faricimab in Macular Edema, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 28 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab administered by intravitreal (IVT) injection at a personalized treatment interval (PTI) to participants who enrolled in and completed one of the two Phase III studies, GR40349 (NCT03622580) or GR40398 (NCT03622593), also referred to as the parent studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Faricimab · Other: Sham Procedure
Faricimab will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen.
Also known as: RO6867461, RG7716
The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 16 weeks of this study in order to maintain the masking of the initial faricimab PTI.
Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale
This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
Time frame: From the day of the first dose of faricimab until the end of the study (up to 108 weeks)
Incidence of Ocular Adverse Events in the Fellow Eye
This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the fellow eye (i.e., non-study eye). Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity, and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
Time frame: From the day of the first dose of faricimab until the end of the study (up to 108 weeks)
Incidence and Severity of Non-Ocular Adverse Events, With Severity Determined According to Adverse Event Severity Grading Scale
This is an analysis of participants with at least one non-ocular (systemic) adverse event (AE). Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
Time frame: From the day of the first dose of faricimab until the end of the study (up to 108 weeks)
| Milestone | Faricimab PTI (Prior Faricimab Q8W) | Faricimab PTI (Prior Faricimab PTI) | Faricimab PTI (Prior Aflibercept Q8W) |
|---|---|---|---|
| Started | 493 | 506 | 475 |
| Received at least one dose of study drug | 491 | 500 | 473 |
| Completed | 405 | 407 | 392 |
| Not completed | 88 | 99 | 83 |
| Withdrew: Withdrawal by subject | 24 | 28 | 21 |
| Withdrew: Death | 23 | 23 | 17 |
| Withdrew: Lost to follow-up | 15 | 15 | 12 |
| Withdrew: Final end of study visit not completed | 10 | 11 | 7 |
| Withdrew: Reason not specified | 7 | 11 | 9 |
| Withdrew: Adverse event | 7 | 7 | 7 |
| Withdrew: Physician decision | 1 | 3 | 6 |
| Withdrew: Protocol violation | 1 | 0 | 2 |
| Withdrew: Pregnancy | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
| Participants | Faricimab PTI (Prior Faricimab Q8W) | Faricimab PTI (Prior Faricimab PTI) | Faricimab PTI (Prior Aflibercept Q8W) |
|---|---|---|---|
| Any Adverse Event (AE), Any Severity | 219 | 188 | 197 |
| AE by Severity: Mild | 119 | 109 | 109 |
| AE by Severity: Moderate | 74 | 66 | 74 |
| AE by Severity: Severe | 20 | 10 | 12 |
| AE by Severity: Missing | 6 | 3 | 2 |
| Serious Adverse Event (SAE) | 31 | 15 | 26 |
| AE Leading to Withdrawal from Study Treatment | 3 | 0 | 6 |
| Treatment-related AE | 10 | 10 | 11 |
| Treatment-related SAE | 0 | 1 | 1 |
| Any AE of Special Interest (AESI) | 30 | 14 | 24 |
| AESI: Drop in Visual Acuity Score ≥30 Letters | 23 | 10 | 20 |
| AESI: Associated with Severe IOI | 1 | 1 | 1 |
| AESI: Intervention Required to Prevent Permanent Vision Loss | 6 | 3 | 3 |
| AESI: Suspected Transmission of Infectious Agent by Study Drug | 0 | 0 | 0 |
This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the fellow eye (i.e., non-study eye). Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity, and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
| Participants | Faricimab PTI (Prior Faricimab Q8W) | Faricimab PTI (Prior Faricimab PTI) | Faricimab PTI (Prior Aflibercept Q8W) |
|---|---|---|---|
| Any Adverse Event (AE) | 186 | 185 | 179 |
| Serious Adverse Event (SAE) | 16 | 17 | 15 |
| Any AE of Special Interest (AESI) | 13 | 16 | 14 |
| AESI: Drop in Visual Acuity Score ≥30 Letters | 6 | 9 | 10 |
| AESI: Associated with Severe IOI | 0 | 1 | 1 |
| AESI: Intervention Required to Prevent Permanent Vision Loss | 7 | 6 | 4 |
| AESI: Suspected Transmission of Infectious Agent by Study Drug | 0 | 0 | 0 |
This is an analysis of participants with at least one non-ocular (systemic) adverse event (AE). Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
| Participants | Faricimab PTI (Prior Faricimab Q8W) | Faricimab PTI (Prior Faricimab PTI) | Faricimab PTI (Prior Aflibercept Q8W) |
|---|---|---|---|
| Any Adverse Event (AE), Any Severity | 317 | 295 | 297 |
| AE by Severity: Mild | 91 | 94 | 97 |
| AE by Severity: Moderate | 124 | 124 | 115 |
| AE by Severity: Severe | 102 | 77 | 85 |
| Serious Adverse Event (SAE) | 122 | 100 | 112 |
| AE Leading to Withdrawal from Study Treatment | 2 | 7 | 4 |
| Any AE of Special Interest (AESI) | 0 | 0 | 1 |
| AESI: Drop in Visual Acuity Score ≥30 Letters | 0 | 0 | 1 |
| AESI: Elevated ALT or AST with Either Elevated Bilirubin or Clinical Jaundice | 0 | 0 | 0 |
Collected over From the day of the first dose of faricimab until the end of the study (up to 108 weeks). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Faricimab PTI (Prior Faricimab Q8W) | 23/493 (4.7%) | 158/491 (32.2%) | 233/491 (47.5%) |
| Faricimab PTI (Prior Faricimab PTI) | 23/506 (4.5%) | 124/500 (24.8%) | 213/500 (42.6%) |
| Faricimab PTI (Prior Aflibercept Q8W) | 17/475 (3.6%) | 134/473 (28.3%) | 219/473 (46.3%) |
| Event | Faricimab PTI (Prior Faricimab Q8W) | Faricimab PTI (Prior Faricimab PTI) | Faricimab PTI (Prior Aflibercept Q8W) |
|---|---|---|---|
| CataractEye disorders | 11/491 | 8/500 | 15/473 |
| Cerebrovascular accidentNervous system disorders | 4/491 | 3/500 | 10/473 |
| COVID-19Infections and infestations | 10/491 | 9/500 | 5/473 |
| Myocardial infarctionCardiac disorders | 9/491 | 3/500 | 8/473 |
| Acute kidney injuryRenal and urinary disorders | 8/491 | 5/500 | 5/473 |
| PneumoniaInfections and infestations | 5/491 | 8/500 | 3/473 |
| Cardiac failure congestiveCardiac disorders | 7/491 | 3/500 | 2/473 |
| Diabetic retinal oedemaEye disorders | 7/491 | 0/500 | 2/473 |
| Localised infectionInfections and infestations | 7/491 | 0/500 | 2/473 |
| OsteomyelitisInfections and infestations | 7/491 | 4/500 | 0/473 |
| Event | Faricimab PTI (Prior Faricimab Q8W) | Faricimab PTI (Prior Faricimab PTI) | Faricimab PTI (Prior Aflibercept Q8W) |
|---|---|---|---|
| CataractEye disorders | 65/491 | 60/500 | 63/473 |
| COVID-19Infections and infestations | 63/491 | 49/500 | 46/473 |
| CataractEye disorders | 56/491 | 41/500 | 51/473 |
| Diabetic retinal oedemaEye disorders | 22/491 | 27/500 | 24/473 |
| NasopharyngitisInfections and infestations | 18/491 | 12/500 | 23/473 |
| HypertensionVascular disorders | 18/491 | 20/500 | 23/473 |
| Posterior capsule opacificationEye disorders | 13/491 | 20/500 | 13/473 |
| Diabetic retinopathyEye disorders | 17/491 | 8/500 | 12/473 |
| Posterior capsule opacificationEye disorders | 16/491 | 17/500 | 14/473 |
| Urinary tract infectionInfections and infestations | 16/491 | 15/500 | 16/473 |
A total of 1479 patients consented to enroll in RHONE-X once they completed the parent studies. However, the baseline analysis population includes a total of 1474 participants because 5 participants were excluded from all analyses as an outcome of the GCP non-compliance identified at one of the clinical trial sites.
| Age, Continuous(Years) | Faricimab PTI (Prior Faricimab Q8W) | Faricimab PTI (Prior Faricimab PTI) | Faricimab PTI (Prior Aflibercept Q8W) | Total |
|---|---|---|---|---|
| Mean | 63.4 ± 9.9 | 64.0 ± 9.8 | 63.5 ± 9.4 | 63.6 ± 9.7 |
| Sex: Female, Male(Participants) | Faricimab PTI (Prior Faricimab Q8W) | Faricimab PTI (Prior Faricimab PTI) | Faricimab PTI (Prior Aflibercept Q8W) | Total |
|---|---|---|---|---|
| Female | 191 | 184 | 205 | 580 |
| Male | 302 | 322 | 270 | 894 |
| Ethnicity (NIH/OMB)(Participants) | Faricimab PTI (Prior Faricimab Q8W) | Faricimab PTI (Prior Faricimab PTI) | Faricimab PTI (Prior Aflibercept Q8W) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 68 | 87 | 79 | 234 |
| Not Hispanic or Latino | 415 | 408 | 386 | 1209 |
| Unknown or Not Reported | 10 | 11 | 10 | 31 |
| Race (NIH/OMB)(Participants) | Faricimab PTI (Prior Faricimab Q8W) | Faricimab PTI (Prior Faricimab PTI) | Faricimab PTI (Prior Aflibercept Q8W) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 5 | 4 | 4 | 13 |
| Asian | 54 | 52 | 45 | 151 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Black or African American | 27 | 32 | 25 | 84 |
| White | 392 | 406 | 389 | 1187 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 13 | 12 | 11 | 36 |
Showing the first 100 of 320 sites across 30 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Aug 2020 to primary completion in Oct 2023, 38 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 38 months is above that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Faricimab